最后
医学
银屑病
银屑病性关节炎
皮肤病科
斑块性银屑病
癌症
疾病
内科学
作者
Nicoletta Bernardini,Nevena Skroza,Alessandra Mambrin,Ilaria Proietti,Ersilia Tolino,Patrizia Maddalena,Federica Marraffa,Giovanni Rossi,Salvatore Volpe,Concetta Potenza
摘要
Psoriasis is a multifactorial, chronic, auto- inflammatory disease, with a worldwide prevalence of around 2%, subtended by robust genetic predisposition and autoimmune pathogenic traits. The disease, mainly involving the skin and joints, is featured by erythemato-squamous lesions, with a chronic relapsing course and relevant systemic comorbidities. Apremilast is a novel oral agent that has recently been made available to dermatologists for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. Although it is considered as relatively safe molecule with few contraindications, experience with Apremilast in the real-world setting for cancer patients with moderate-to-severe plaque psoriasis is lacking. Hence, we report the real-life experience in patients with psoriasis and a history of cancer who underwent treatment with Apremilast for 104 weeks.
科研通智能强力驱动
Strongly Powered by AbleSci AI